Welcome to our dedicated page for Inovio Pharmaceu news (Ticker: INO), a resource for investors and traders seeking the latest updates and insights on Inovio Pharmaceu stock.
Inovio Pharmaceuticals reports developments in DNA medicines for HPV-related diseases, cancer and infectious diseases. Its updates center on INO-3107, a DNA immunotherapy candidate for recurrent respiratory papillomatosis, including clinical data, scientific publications, FDA review milestones and presentations at medical and biotechnology conferences.
Company news also includes quarterly and annual financial results, business updates, research on DNA-encoded monoclonal antibodies and DNA-encoded protein technology, collaboration activity and capital-structure actions involving common stock, warrants and at-the-market financing programs.
INOVIO (Nasdaq: INO) announced on November 10, 2025 that it intends to offer and sell shares of its common stock in an underwritten public offering, with all shares to be sold by the company.
INOVIO said it will grant the underwriter a 30-day option to buy up to 15% additional shares on the same terms. The offering is subject to market conditions and there is no assurance of timing, size, or terms. Piper Sandler is acting as sole book-running manager. The shares are covered by a shelf registration filed with the SEC on November 9, 2023 and declared effective on January 31, 2024. The offering will be made only by prospectus and prospectus supplement filed with the SEC.
INOVIO (NASDAQ: INO) completed a rolling BLA submission for INO-3107 under FDA accelerated approval and requested priority review; company expects file acceptance by year-end 2025 with a potential PDUFA in mid-2026 if priority review is granted. Commercial preparations target a potential mid-2026 launch and a confirmatory trial is planned to begin during review at ~20 U.S. sites. Clinical highlights: 81% of patients had fewer surgeries at Year 1 and a 78% mean annual surgery reduction at Year 2 versus pre-treatment. Scientific progress includes a Nature Medicine publication on next-generation DMAb technology. Q3 2025 results: R&D $13.3M, G&A $7.9M, total operating expenses $21.2M, net loss $45.5M ($0.87/share) driven by a $22.5M non-cash warrant fair-value loss. Cash $50.8M vs $94.1M at 12/31/24; runway into Q2 2026 with estimated Q4 burn ~$22M.
INOVIO (NASDAQ: INO) completed the rolling submission of a Biologics License Application (BLA) for INO-3107, a DNA immunotherapy for recurrent respiratory papillomatosis (RRP) in adults, submitted under the FDA's Accelerated Approval program.
The program includes prior Orphan Drug and Breakthrough Therapy designations. The company expects FDA file acceptance by year-end 2025 and, if priority review is granted, a potential PDUFA date in mid-2026. If approved, INO-3107 would be INOVIO's first commercial product and the first DNA medicine available in the United States.
INOVIO (NASDAQ:INO) announced an inducement equity award under its 2022 Inducement Plan with a grant date of October 31, 2025.
The Compensation Committee approved an option to purchase 3,000 shares of common stock at an exercise price of $2.35 (the closing price on October 31, 2025). The option vests in thirds over three years (one-third on each of the first, second and third anniversaries) and is subject to continued employment and the Inducement Plan option agreement terms. The award was made to a newly hired employee in accordance with Nasdaq Listing Rule 5635(c)(4).
INOVIO (NASDAQ:INO) announced its Q3 2025 financial results will be released after market close on November 10, 2025.
The company will host a live conference call and webcast at 4:30 p.m. ET the same day to discuss results and provide a business update. The webcast is listen-only with a live Q&A with analysts and will be archived for 90 days at the company investor site.
INOVIO (NASDAQ: INO) will participate in a virtual fireside chat at the Stephens Biotechnology Virtual Fireside Chat Conference on November 4, 2025 from 3:00–3:50 PM ET. Management will also hold one-on-one investor meetings during the conference. The event is virtual and will not offer a replay or transcript. Investors seeking to join meetings or obtain more information should contact their Stephens representative.
INOVIO (NASDAQ: INO) announced that Phase 1 proof-of-concept DMAb data for COVID-19 were published in Nature Medicine on Oct 21, 2025.
Key findings: all 39 participants maintained biologically relevant DMAb levels through week 72, expressed antibodies bound SARS-CoV-2 Spike and neutralized pseudovirus, and no anti-drug antibodies were detected across ~1,000 blood samples. DMAbs were well tolerated; most adverse events were mild, temporary injection-site reactions and no SAEs were linked to the study drug. Investigators continue exploratory sample analyses.
INOVIO (NASDAQ:INO), a biotechnology company specializing in DNA medicines, has announced an equity grant under its 2022 Inducement Plan to a newly hired employee. The Compensation Committee approved a stock option award to purchase 1,302 shares of common stock with an exercise price of $2.34 per share, effective September 30, 2025.
The stock option will vest over three years, with one-third of shares vesting annually on the grant date anniversary. Vesting is contingent upon continued employment with INOVIO.
INOVIO (NASDAQ: INO), a biotechnology company, has announced its participation in multiple upcoming scientific conferences to present data on its lead product candidate INO-3107 for Recurrent Respiratory Papillomatosis (RRP) and next-generation DNA medicine technology.
The company has initiated a rolling Biologics License Application (BLA) submission for INO-3107, with plans to complete the submission in H2 2025 and targeting FDA file acceptance by year-end. The presentations will take place across various conferences including the American Academy of Otolaryngology Annual Meeting, World Vaccine Congress Europe, and ESMO Congress.
Additionally, INOVIO will present the first preclinical data on DNA-encoded protein technology (DPROT) for Hemophilia A and showcase developments in DNA-encoded monoclonal antibody (DMAb) technology.
INOVIO (NASDAQ: INO) announced FDA's agreement to their rolling submission timeline for the Biologics License Application (BLA) for INO-3107, a treatment for adults with Recurrent Respiratory Papillomatosis (RRP). The company plans to complete the BLA submission in the coming months and will request priority review, targeting FDA file acceptance by the end of 2025.
The treatment has received Breakthrough Therapy designation and INOVIO is actively engaging with the FDA to expedite the approval process. The company believes INO-3107 could become the preferred treatment option for RRP patients and healthcare providers.